Isomorphic Labs, Google's A.I. Drug Business, Raises Money From Thrive

In the last year, Google has significantly advanced AI-driven drug design, leading to major breakthroughs that mimic human biology. This success resulted in a Nobel Prize in Chemistry awarded to leading scientists at Google. Isomorphic Labs, a spinoff of Google’s DeepMind, is set to announce raising $600 million from Thrive Capital and others to further its mission. The lab utilizes advanced software, including AlphaFold, to optimize drug development by predicting protein structures and biological responses, aiming to streamline the drug discovery process and reduce reliance on traditional labs.

Over the past year, Google’s AI innovations have notably advanced drug design, culminating in a Nobel Prize in Chemistry for its top scientists and the establishment of Isomorphic Labs.

Isomorphic Labs has announced a $600 million funding round led by Thrive Capital, showcasing Google’s commitment to revolutionizing drug discovery with advanced artificial intelligence technologies.

Read at www.nytimes.com